TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.38% | 52.27% | 41.97% | 44.40% | 41.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.38% | 52.27% | 41.97% | 44.40% | 41.52% |
| Cost of Revenue | 89.84% | 97.59% | 53.96% | 108.93% | 70.46% |
| Gross Profit | 52.25% | 45.86% | 39.85% | 37.09% | 37.81% |
| SG&A Expenses | 24.23% | 28.71% | 3.46% | 15.14% | 15.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.92% | 19.35% | -9.01% | -12.07% | -17.42% |
| Operating Income | -3.15% | 10.30% | 37.21% | 34.70% | 38.84% |
| Income Before Tax | -349.88% | -91.70% | 21.46% | 71.63% | -68.56% |
| Income Tax Expenses | 266.67% | -142.86% | 66.67% | -200.00% | -- |
| Earnings from Continuing Operations | -350.65% | -91.32% | 21.44% | 71.64% | -68.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -350.65% | -91.32% | 21.44% | 71.64% | -68.35% |
| EBIT | -3.15% | 10.30% | 37.21% | 34.70% | 38.84% |
| EBITDA | -3.44% | 10.19% | 37.75% | 35.17% | 39.45% |
| EPS Basic | -693.54% | -6.94% | 35.30% | 74.80% | 15.47% |
| Normalized Basic EPS | -72.31% | 63.84% | 15.27% | 64.33% | 86.09% |
| EPS Diluted | -693.54% | -6.94% | 35.30% | 74.80% | 15.47% |
| Normalized Diluted EPS | -72.31% | 63.84% | 15.27% | 64.33% | 86.09% |
| Average Basic Shares Outstanding | 62.47% | 38.01% | 22.31% | 18.59% | 101.18% |
| Average Diluted Shares Outstanding | 62.47% | 38.01% | 22.31% | 18.59% | 101.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |